# Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness

> **NCT03321045** · EARLY_PHASE1 · RECRUITING · sponsor: **University of Alabama at Birmingham** · enrollment: 10 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** [89Zr]-Df-Trastuzumab
- **DIAGNOSTIC_TEST:** PET/MRI Imaging

## Key facts

- **NCT ID:** NCT03321045
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-11-21
- **Primary completion:** 2028-10
- **Final completion:** 2028-10
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03321045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03321045, "Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03321045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*